aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from "LIFE" to "ATYR"

Company Overview - aTyr Pharma, Inc. is a clinical stage biotechnology company focused on discovering and developing first-in-class medicines from its proprietary tRNA synthetase platform [1][2] - The company is advancing its lead therapeutic candidate, efzofitimod, through a pivotal Phase 3 study in pulmonary sarcoidosis, with potential commercialization on the horizon [1][2] Ticker Symbol Change - The company will change its ticker symbol from "LIFE" to "ATYR," effective June 5, 2024, to better reflect its corporate identity and enhance visibility [1] - Existing stockholders do not need to take any action regarding the ticker symbol change, and the common stock will continue to be listed on the Nasdaq Capital Market [1] Therapeutic Focus - aTyr's lead candidate, efzofitimod, is a first-in-class biologic immunomodulator in clinical development for treating interstitial lung disease, which includes immune-mediated disorders causing lung inflammation and progressive fibrosis [2]